Frazier Healthcare Partners
VC Fund
Seattle, United States
Frazier Healthcare Partners is a VC fund in Seattle focused on Biotechnology and Health Care. Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.Frazier’sexperienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
- Total investments:
- 182
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $2.3B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Frazier Healthcare Partners invests in
Stages Frazier Healthcare Partners invests in
Countries Frazier Healthcare Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Round size
- Series A
- $10M–$73M
- Series B
- $10M–$110M
- Post-IPO Equity
- $15M–$200M
Investment Focus
Industry
- Biotechnology 105 (58%)
- Health Care 81 (45%)
- Therapeutics 50 (27%)
- Pharmaceutical 45 (25%)
- Medical 36 (20%)
Stage
- Series B 42 (23%)
- Series A 35 (19%)
- Post-IPO Equity 24 (13%)
- Series C 19 (10%)
- Series D 16 (9%)
Country
- United States 116 (64%)
- Canada 3 (2%)
- Ireland 2 (1%)
- China 1 (1%)
- Singapore 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Nathan Every
General Partner
|
General Partner | Total investments: 11 | Find email | |
Patrick Heron
General Partner
|
General Partner | Total investments: 17 | Find email | |
Tadataka Yamada
Senior Entrepreneur in Residence
|
Senior Entrepreneur in Residence | Total investments: 1 | Find email | |
Alan D. Frazier
Managinig Partner, Founder & Chairman
|
Managinig Partner, Founder & Chairman | Total investments: 6 | Find email | |
Bob Baltera
Entrepreneurs In Residence
|
Entrepreneurs In Residence | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Iolyx Therapeutics is a biotechnology research and healthcare service provider for ocular diseases. | $15M / Series B / Dec 03, 2025 | ||
| J. Knipper & Company's mission is to work with theiour clients to create solutions that are strategically designed, faithfully executed, and driven by market insight and data to ensure maximum return on their clients’ investment, and ultimately to improve people’s lives. Their services, ranging from direct marketing and sampling through todata analytics and Web-based applications, are grounded in robust systems and regulatory rigor, as well as years of seeing what works and what doesn’t. | Private Equity / Jul 08, 2025 | ||
| Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $175M / Post-IPO Equity / Jul 30, 2024 | ||
| Curve Beam is a manufacturer that researches and designs cone beam CT imaging equipment for orthopedic specialties. | $25M / Venture - Series Unknown / Jan 31, 2023 | ||
| NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $235M / Post-IPO Equity / Nov 23, 2022 | ||
| Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M / Series B / Jan 25, 2022 | ||
| Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner. | $75M / Post-IPO Equity / Dec 27, 2021 | ||
|
SanReno Therapeutics
|
SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China. | $40M / Nov 30, 2021 | |
| Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed toaccelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death. | $42M / Post-IPO Equity / Nov 15, 2021 | ||
| Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. | $20M / Post-IPO Equity / Nov 05, 2021 | ||
| See all 182 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Frazier Healthcare Partners invest in?
Frazier Healthcare Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 182 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Frazier Healthcare Partners's check size?
Frazier Healthcare Partners typically joins rounds of $10M–$73M at Series A, $10M–$110M at Series B and $15M–$200M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Frazier Healthcare Partners participates in.
How do I contact Frazier Healthcare Partners?
Public channels for Frazier Healthcare Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Frazier Healthcare Partners?
The team at Frazier Healthcare Partners includes Nathan Every (General Partner), Patrick Heron (General Partner) and Tadataka Yamada (Senior Entrepreneur in Residence), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
